New drug duo aims to wipe out hidden leukemia cells
NCT ID NCT07271667
First seen Jan 05, 2026 · Last updated Apr 30, 2026 · Updated 12 times
Summary
This study tests whether adding emavusertib to an approved BTK inhibitor (zanubrutinib) can improve outcomes for adults with chronic lymphocytic leukemia or other B-cell cancers. About 108 participants will receive the combination to see if it leads to undetectable cancer cells or tumor shrinkage. The goal is to better control the disease, not cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mt Sinai Comprehensive Cancer Center
RECRUITINGMiami Beach, Florida, 33140, United States
-
Ohio State University Comprehensive Cancer Center
RECRUITINGColumbus, Ohio, 43210, United States
-
Texas Oncology - Sammons Cancer Center
RECRUITINGDallas, Texas, 75246, United States
Conditions
Explore the condition pages connected to this study.